Ibuprofen treatment after the first days of life in preterm neonates with patent ductus arteriosus
Aim: Patent ductus arteriosus (PDA) is treated with ibuprofen and it is known that the clearance of ibuprofen increases with postnatal age. We aimed to study whether postnatal age-adjusted ibuprofen dosages improve the effectiveness of treatment compared to standard ibuprofen dosages after the first days of life. Methods: A historical cohort of 207 preterm neonates treated with standard ibuprofen dosages (Group A; 2011–2015) was compared to a prospective cohort of 66 preterm neonates treated with postnatal age-adjusted ibuprofen dosages (Group B; 2015–2016). Results: Both groups had comparable background characteristics. Treatment was started after median 6 (25–75th percentile: 4–11) and 5 (25–75th percentile: 4–11) days and effectiveness was 33.2 and 44.7% (p =.17) in groups A and B, respectively. No hemodynamically significant PDA was found in 23/49 (46.9%) of the patients born before 28 weeks after adjusted ibuprofen dosages compared to 48/162 (29.6%) after standard ibuprofen dosages (p =.04). There were significantly more reversible side effects with the postnatal age-adjusted ibuprofen dosages (p =.04). Conclusions: There seems to be a trend to higher effectiveness with the adjusted ibuprofen dosages in preterm neonates before 28 weeks, but it is associated with more reversible side effects.
|Keywords||development, dosing, ibuprofen, Patent ductus arteriosus, pharmacodynamics, preterm neonates|
|Persistent URL||dx.doi.org/10.1080/14767058.2019.1667323, hdl.handle.net/1765/120618|
|Journal||The Journal of Maternal - Fetal & Neonatal Medicine|
de Klerk, J.C.A, van Paassen, N. (Nanda), van Beynum, I.M, Flint, R.B, Reiss, I.K.M, & Simons, S.H. (2019). Ibuprofen treatment after the first days of life in preterm neonates with patent ductus arteriosus. The Journal of Maternal - Fetal & Neonatal Medicine. doi:10.1080/14767058.2019.1667323